Oral etoposide in heavily pre-treated metastatic breast cancer

A retrospective series

G. Giannone, A. Milani, E. Ghisoni, S. Genta, G. Mittica, F. Montemurro, G. Valabrega

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Patients with metastatic breast cancer (MBC) can derive clinical benefit from several subsequent lines of chemotherapy. However, in heavily pre-treated patients, agents with clinical activity, a favourable side effects profile and a convenient administration modality are preferred. Patients and Methods: We retrospectively analyzed 110 patients with previously treated MBC, who received oral etoposide at the dose of 50 mg/day for 20 days in 28 days cycles, between 2003 and 2017. Because this was not a prospectively planned study, to describe the clinical performance of oral etoposide we adopted the approach suggested by Dzimitrowicz and colleagues (J Clin Oncol. 2016; 34:3511–17); Tumour Response (TR) was defined as the proportion of physician-reported clinical or imaging response; Prolonged Duration on Therapy (PDT) as the proportion of non-progressing patients whose treatment lasted more than 6 months. Furthermore, we evaluated median duration on therapy (TD) and median Overall Survival (OS) by the Kaplan Meier method. Results: The median number of previous chemotherapy lines was 5 (range 2–8). TR, PDT, median TD and median OS were 6.4%, 18.2% 4 (range 3.5–4.5) and 10.6 (range 8.4–12.8) months respectively. Interestingly, etoposide activity was unrelated to the number of previous lines and type of metastatic involvement. Oral etoposide was well tolerated with only two patients discontinuing therapy due to toxicity. Conclusions: In this large, single Institution, real practice analysis oral etoposide is a valuable and safe option for pre-treated metastatic breast cancer patients and might be considered in patients failing other approaches, but still suitable for chemotherapy.

Original languageEnglish
Pages (from-to)160-164
Number of pages5
JournalBreast
Volume38
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Etoposide
Breast Neoplasms
Drug Therapy
Therapeutics
Survival
Proxy
Neoplasms
Physicians

Keywords

  • Heavily pretreated
  • Low dose chemotherapy
  • Metastatic breast cancer
  • Oral etoposide

ASJC Scopus subject areas

  • Surgery

Cite this

Oral etoposide in heavily pre-treated metastatic breast cancer : A retrospective series. / Giannone, G.; Milani, A.; Ghisoni, E.; Genta, S.; Mittica, G.; Montemurro, F.; Valabrega, G.

In: Breast, Vol. 38, 01.04.2018, p. 160-164.

Research output: Contribution to journalArticle

@article{c0ad44175d83418e8084ac7ae70c0fcc,
title = "Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series",
abstract = "Background: Patients with metastatic breast cancer (MBC) can derive clinical benefit from several subsequent lines of chemotherapy. However, in heavily pre-treated patients, agents with clinical activity, a favourable side effects profile and a convenient administration modality are preferred. Patients and Methods: We retrospectively analyzed 110 patients with previously treated MBC, who received oral etoposide at the dose of 50 mg/day for 20 days in 28 days cycles, between 2003 and 2017. Because this was not a prospectively planned study, to describe the clinical performance of oral etoposide we adopted the approach suggested by Dzimitrowicz and colleagues (J Clin Oncol. 2016; 34:3511–17); Tumour Response (TR) was defined as the proportion of physician-reported clinical or imaging response; Prolonged Duration on Therapy (PDT) as the proportion of non-progressing patients whose treatment lasted more than 6 months. Furthermore, we evaluated median duration on therapy (TD) and median Overall Survival (OS) by the Kaplan Meier method. Results: The median number of previous chemotherapy lines was 5 (range 2–8). TR, PDT, median TD and median OS were 6.4{\%}, 18.2{\%} 4 (range 3.5–4.5) and 10.6 (range 8.4–12.8) months respectively. Interestingly, etoposide activity was unrelated to the number of previous lines and type of metastatic involvement. Oral etoposide was well tolerated with only two patients discontinuing therapy due to toxicity. Conclusions: In this large, single Institution, real practice analysis oral etoposide is a valuable and safe option for pre-treated metastatic breast cancer patients and might be considered in patients failing other approaches, but still suitable for chemotherapy.",
keywords = "Heavily pretreated, Low dose chemotherapy, Metastatic breast cancer, Oral etoposide",
author = "G. Giannone and A. Milani and E. Ghisoni and S. Genta and G. Mittica and F. Montemurro and G. Valabrega",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.breast.2018.01.006",
language = "English",
volume = "38",
pages = "160--164",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Oral etoposide in heavily pre-treated metastatic breast cancer

T2 - A retrospective series

AU - Giannone, G.

AU - Milani, A.

AU - Ghisoni, E.

AU - Genta, S.

AU - Mittica, G.

AU - Montemurro, F.

AU - Valabrega, G.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Patients with metastatic breast cancer (MBC) can derive clinical benefit from several subsequent lines of chemotherapy. However, in heavily pre-treated patients, agents with clinical activity, a favourable side effects profile and a convenient administration modality are preferred. Patients and Methods: We retrospectively analyzed 110 patients with previously treated MBC, who received oral etoposide at the dose of 50 mg/day for 20 days in 28 days cycles, between 2003 and 2017. Because this was not a prospectively planned study, to describe the clinical performance of oral etoposide we adopted the approach suggested by Dzimitrowicz and colleagues (J Clin Oncol. 2016; 34:3511–17); Tumour Response (TR) was defined as the proportion of physician-reported clinical or imaging response; Prolonged Duration on Therapy (PDT) as the proportion of non-progressing patients whose treatment lasted more than 6 months. Furthermore, we evaluated median duration on therapy (TD) and median Overall Survival (OS) by the Kaplan Meier method. Results: The median number of previous chemotherapy lines was 5 (range 2–8). TR, PDT, median TD and median OS were 6.4%, 18.2% 4 (range 3.5–4.5) and 10.6 (range 8.4–12.8) months respectively. Interestingly, etoposide activity was unrelated to the number of previous lines and type of metastatic involvement. Oral etoposide was well tolerated with only two patients discontinuing therapy due to toxicity. Conclusions: In this large, single Institution, real practice analysis oral etoposide is a valuable and safe option for pre-treated metastatic breast cancer patients and might be considered in patients failing other approaches, but still suitable for chemotherapy.

AB - Background: Patients with metastatic breast cancer (MBC) can derive clinical benefit from several subsequent lines of chemotherapy. However, in heavily pre-treated patients, agents with clinical activity, a favourable side effects profile and a convenient administration modality are preferred. Patients and Methods: We retrospectively analyzed 110 patients with previously treated MBC, who received oral etoposide at the dose of 50 mg/day for 20 days in 28 days cycles, between 2003 and 2017. Because this was not a prospectively planned study, to describe the clinical performance of oral etoposide we adopted the approach suggested by Dzimitrowicz and colleagues (J Clin Oncol. 2016; 34:3511–17); Tumour Response (TR) was defined as the proportion of physician-reported clinical or imaging response; Prolonged Duration on Therapy (PDT) as the proportion of non-progressing patients whose treatment lasted more than 6 months. Furthermore, we evaluated median duration on therapy (TD) and median Overall Survival (OS) by the Kaplan Meier method. Results: The median number of previous chemotherapy lines was 5 (range 2–8). TR, PDT, median TD and median OS were 6.4%, 18.2% 4 (range 3.5–4.5) and 10.6 (range 8.4–12.8) months respectively. Interestingly, etoposide activity was unrelated to the number of previous lines and type of metastatic involvement. Oral etoposide was well tolerated with only two patients discontinuing therapy due to toxicity. Conclusions: In this large, single Institution, real practice analysis oral etoposide is a valuable and safe option for pre-treated metastatic breast cancer patients and might be considered in patients failing other approaches, but still suitable for chemotherapy.

KW - Heavily pretreated

KW - Low dose chemotherapy

KW - Metastatic breast cancer

KW - Oral etoposide

UR - http://www.scopus.com/inward/record.url?scp=85041429658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041429658&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2018.01.006

DO - 10.1016/j.breast.2018.01.006

M3 - Article

VL - 38

SP - 160

EP - 164

JO - Breast

JF - Breast

SN - 0960-9776

ER -